AZRE is a mid-size pharmaceutical firm specializing in drugs to manage pain. They currently have a...

Transcribed Image Text:

AZRE is a mid-size pharmaceutical firm specializing in drugs to manage pain. They currently have a drug, NoMoPane, which is ready for (Phase III) clinical trials. The clinical trials will cost AZRE a total of $100 million in present value. If they make this investment, there is a 20 percent chance that NoMoPane will be successful in obtaining FDA approval. If NoMoPane is not approved, you may assume that it is worthless. If the drug is approved, AZRE believes it has a 60% chance of being available only as a "scheduled substance" which requires special handling in pharmacies and hospitals and would greatly limit sales. (Powerful narcotics like morphine are scheduled substances.) If NoMoPane is a scheduled substance, the present value of the drug is estimated to be $90 million. If NoMoPane is not a scheduled substance, it will be available more broadly by prescription and the present value of the drug is estimated at $1000 million. If they do invest in the clinical trials, what is the probability that they will have a positive present value? ↑ X₂ B I E U A 12pt fx A x를 ≡ Paragraph s E S There is some debate at AZRE about the probability of obtaining FDA approval and whether 20 percent is the right number to assume. At what probability would your recommendation in question 2 change? [You may assume that the probability of NoMoPane being a scheduled substance does not change if you change the probability obtaining FDA approval.] AZRE is a mid-size pharmaceutical firm specializing in drugs to manage pain. They currently have a drug, NoMoPane, which is ready for (Phase III) clinical trials. The clinical trials will cost AZRE a total of $100 million in present value. If they make this investment, there is a 20 percent chance that NoMoPane will be successful in obtaining FDA approval. If NoMoPane is not approved, you may assume that it is worthless. If the drug is approved, AZRE believes it has a 60% chance of being available only as a "scheduled substance" which requires special handling in pharmacies and hospitals and would greatly limit sales. (Powerful narcotics like morphine are scheduled substances.) If NoMoPane is a scheduled substance, the present value of the drug is estimated to be $90 million. If NoMoPane is not a scheduled substance, it will be available more broadly by prescription and the present value of the drug is estimated at $1000 million. If they do invest in the clinical trials, what is the probability that they will have a positive present value? ↑ X₂ B I E U A 12pt fx A x를 ≡ Paragraph s E S There is some debate at AZRE about the probability of obtaining FDA approval and whether 20 percent is the right number to assume. At what probability would your recommendation in question 2 change? [You may assume that the probability of NoMoPane being a scheduled substance does not change if you change the probability obtaining FDA approval.] AZRE is a mid-size pharmaceutical firm specializing in drugs to manage pain. They currently have a drug, NoMoPane, which is ready for (Phase III) clinical trials. The clinical trials will cost AZRE a total of $100 million in present value. If they make this investment, there is a 20 percent chance that NoMoPane will be successful in obtaining FDA approval. If NoMoPane is not approved, you may assume that it is worthless. If the drug is approved, AZRE believes it has a 60% chance of being available only as a "scheduled substance" which requires special handling in pharmacies and hospitals and would greatly limit sales. (Powerful narcotics like morphine are scheduled substances.) If NoMoPane is a scheduled substance, the present value of the drug is estimated to be $90 million. If NoMoPane is not a scheduled substance, it will be available more broadly by prescription and the present value of the drug is estimated at $1000 million. If they do invest in the clinical trials, what is the probability that they will have a positive present value? ↑ X₂ B I E U A 12pt fx A x를 ≡ Paragraph s E S There is some debate at AZRE about the probability of obtaining FDA approval and whether 20 percent is the right number to assume. At what probability would your recommendation in question 2 change? [You may assume that the probability of NoMoPane being a scheduled substance does not change if you change the probability obtaining FDA approval.] AZRE is a mid-size pharmaceutical firm specializing in drugs to manage pain. They currently have a drug, NoMoPane, which is ready for (Phase III) clinical trials. The clinical trials will cost AZRE a total of $100 million in present value. If they make this investment, there is a 20 percent chance that NoMoPane will be successful in obtaining FDA approval. If NoMoPane is not approved, you may assume that it is worthless. If the drug is approved, AZRE believes it has a 60% chance of being available only as a "scheduled substance" which requires special handling in pharmacies and hospitals and would greatly limit sales. (Powerful narcotics like morphine are scheduled substances.) If NoMoPane is a scheduled substance, the present value of the drug is estimated to be $90 million. If NoMoPane is not a scheduled substance, it will be available more broadly by prescription and the present value of the drug is estimated at $1000 million. If they do invest in the clinical trials, what is the probability that they will have a positive present value? ↑ X₂ B I E U A 12pt fx A x를 ≡ Paragraph s E S There is some debate at AZRE about the probability of obtaining FDA approval and whether 20 percent is the right number to assume. At what probability would your recommendation in question 2 change? [You may assume that the probability of NoMoPane being a scheduled substance does not change if you change the probability obtaining FDA approval.]

Answer rating: 100% (QA)

Lets break down the problem step by step Probability of FDA Approval AZRE has a 20 chance of NoMoPane obtaining FDA approval Probability of NoMoPane B... View the full answer